I am a
Home I AM A Search Login

Papers of the Week

Papers: 15 Jan 2022 - 21 Jan 2022

Human Studies

2022 Jan 17

J Headache Pain



Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000-201).


Johnston K, Harris L, Powell L, Popoff E, Coric V, L'italien G, Schreiber CP
J Headache Pain. 2022 Jan 17; 23(1):10.
PMID: 35038983.


The objective of this study was to describe patterns in monthly migraine days (MMD) and tablet utilization, and to estimate health-related quality of life (HRQoL) measures in patients treated as needed (PRN) with rimegepant 75 mg over 52-weeks.